Changchun High-Tech Industry (Group) Co., Ltd. (000661.SZ) announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd. ("Jinsai Pharma"), has received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration (NMPA). The clinical trial application for Jinsai Pharma's GenSci142 capsule has been approved.
GenSci142 capsule is a Class 1 innovative biological product developed by Jinsai Pharma, intended for the treatment of bacterial vaginosis.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.